All In Biotech

Drug Trial Radar · NCT01188928

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

A Phase 3 Study Comparing Once Daily Treatment With Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension With Betamethasone 0.5 mg/g (as Dipropionate) in the Topical Suspension Vehicle, Calcipotriol 50 mcg/g in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Subjects With Psoriasis Vulgaris on Non-scalp Regions of the Body (Trunk and/or Limbs)

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,152

Actual

Start

Sep 2010

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Aug 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the topical suspension vehicle (betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle) and with the topical suspension vehicle alone in the treatment of psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs) in a large phase 3 study. This comparison will ensure a more informed assessment of the benefit/risk ratio of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension while also establishing the optimal treatment duration in psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs).

Conditions

  • Psoriasis Vulgaris

Interventions

  • Calcipotriol plus betamethasoneDrug

    Topical suspension once daily for up to 8 weeks.

  • Betamethasone-17,21-dipropionateDrug

    Topical suspension once daily for up to 8 weeks.

  • CalcipotrieneDrug

    Topical suspension once daily for up to 8 weeks.

  • Topical suspension vehicleDrug

    Topical suspension once daily for up to 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4Time frame: 4 weeks
  2. Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8Time frame: week 8

Locations

59 sites in 1 country. Site status is shown where the registry gives one.

  • Horizon Research Group, Inc

    Mobile, Alabama

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Advanced Clinical Research Institute

    Anaheim, California

  • DBA Torrance Clinical Research

    Lomita, California

  • Dermatology Specialists, Inc.

    Oceanside, California

  • Skin Surgery Medical Group, Inc.

    San Diego, California

  • Walter Nahm, MD, Ph.D., Inc

    San Diego, California

  • Coastal Medical Research Group, Inc.

    San Luis Obispo, California

  • Clinical Science Institute

    Santa Monica, California

  • Dermatology Research Centers

    Santa Monica, California

  • Colorado Medical Research Center, Inc.

    Denver, Colorado

  • Horizons Clinical Research Center, LLC

    Denver, Colorado

  • Visions Clinical Research

    Boynton Beach, Florida

  • Dermatology Associates and Research

    Coral Gables, Florida

  • North Florida Dermatology Associates, PA

    Jacksonville, Florida

  • International Dermatology Research, Inc.

    Miami, Florida

  • Ameriderm Research

    Ormond Beach, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Atlanta Dermatology, Vein & Research Center

    Alpharetta, Georgia

  • Peachtree Dermatology Associates

    Atlanta, Georgia

  • Dermatologic Surgery Specialists, PC

    Macon, Georgia

  • Gwinnett Clinical Research Center, Inc

    Snellville, Georgia

  • Altman Dermatology Associates

    Arlington Hts, Illinois

  • Glazer Dermatology

    Buffalo Grove, Illinois

  • Deaconess Clinic, Inc.

    Evansville, Indiana

  • Hudson Dermatology

    Evansville, Indiana

  • Dawes Fretzin Clinical Research Group

    Indianapolis, Indiana

  • Indiana Clinical Trials Center

    Plainfield, Indiana

  • Dermatology Specialists

    Louisville, Kentucky

  • Owensboro Dermatology Associates

    Owensboro, Kentucky

  • Lawrence J. Green, MD, LLC

    Rockville, Maryland

  • David Fivenson, MD Dermatology, PLC

    Ann Arbor, Michigan

  • Great Lakes Research Group, Inc

    Bay City, Michigan

  • Michigan Center for Research Corp.,

    Clinton Township, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Hamzavi Dermatology

    Fort Gratiot, Michigan

  • Somerset Skin Centre

    Troy, Michigan

  • Grekin Skin Institute

    Warren, Michigan

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • Karl G. Heine, M. D. Dermatology

    Henderson, Nevada

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.